The trial is a randomized, open label, comparative trial. Subjects with Iron Deficiency Anemia (IDA) will be randomized to one treatment course of one of the following treatments:
Group A: Iron Isomaltoside 1000 (Monofer) IV
Group B: Ferric Carboxymaltose (Ferinject/ Injectafer) IV
Subjects, who fullfill the following elegibility criteria, will be included:
Men or Woman >18 years having Iron Deficiency Anemia
Hb ≤ 11g/dL
Body weight > 50 kg
S- Ferritin ≤ 100 ng/mL
Estimate glomerular filtration rate (eGFR) ≥ 65 mL/min/ 1.73 m²
S-phosphate > 2.5 mg/dL